InsidersTradesSigma
Track the Reneo Pharmaceuticals, Inc. share price and the full insider trade history of the company, a publicly traded company based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Reneo Pharmaceuticals, Inc. has published 30 insider filings. The latest transaction was filed on 26 September 2024 (Acquisition). Among the most active insiders: Muralidhar Bali. Every trade is free.
30
Insider Decl.
n/a
Thresholds
€3m
18 ops.
Buy Volume
€1m
2 ops.
Sell Volume
49Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 26 September 2024
Declarations30 total
29,600 shares@ US$1.41447.8% of flowCommon StockSEC:0001373604-24-000098:0
Canonical exit: 23 Dec 2024 (T+90)
55,300 shares@ US$1.358214.0% of flowCommon StockSEC:0001373604-24-000094:0
Canonical exit: 16 Dec 2024 (T+90)
36,176 shares@ US$1.39669.5% of flowCommon StockSEC:0001373604-24-000090:0
Canonical exit: 11 Dec 2024 (T+90)
171,339 shares@ US$1.392545.0% of flowCommon StockSEC:0001373604-24-000071:0
Canonical exit: 11 Nov 2024 (T+90)
79,281 shares@ US$1.5623.7% of flowCommon StockSEC:0001373604-24-000028:0
Canonical exit: 12 Aug 2024 (T+90)
15,625 shares@ US$1.80100.0% of flowCommon StockSEC:0001209191-23-047626:0
50,000 shares0Common StockSEC:0001209191-23-043558:0
100,000 shares@ US$7.0974100.0% of flowCommon StockSEC:0001209191-23-039541:0
125,000 shares@ US$8.00100.0% of flowCommon StockSEC:0001209191-23-028533:0
Canonical exit: 6 Aug 2023 (T+90)
22,348 shares0Common StockSEC:0001209191-22-061032:0
7,500 shares@ US$3.39344.5% of flowCommon StockSEC:0001209191-22-048534:0
Canonical exit: 30 Nov 2022 (T+90)
50,000 shares@ US$1.97100.0% of flowCommon StockSEC:0001209191-22-048532:0
83 shares@ US$3.240.5% of flowCommon StockSEC:0001209191-22-048167:0
Canonical exit: 27 Nov 2022 (T+90)
100,000 shares0Common StockSEC:0001209191-21-069443:0
25,000 shares0Common StockSEC:0001209191-21-069436:0
30,000 shares0Common StockSEC:0001209191-21-069439:0
30,000 shares0Common StockSEC:0001209191-21-069448:0
30,000 shares0Common StockSEC:0001209191-21-064587:0
5,000 shares@ US$7.4353100.0% of flowCommon StockSEC:0001209191-21-053523:0
Canonical exit: 23 Nov 2021 (T+90)
8,000 shares@ US$8.00100.0% of flowCommon StockSEC:0001209191-21-053522:0
Canonical exit: 23 Nov 2021 (T+90)
2,500 shares@ US$7.446438.0% of flowCommon StockSEC:0001209191-21-053520:0
Canonical exit: 23 Nov 2021 (T+90)
111,736 shares@ US$8.5081.2% of flowCommon StockSEC:0001209191-21-046802:0
111,736 shares@ US$8.5054.3% of flowCommon StockSEC:0001209191-21-046803:0
Canonical exit: 12 Oct 2021 (T+90)
111,736 shares@ US$1.9718.8% of flowCommon StockSEC:0001209191-21-046254:0
20,710 shares@ US$9.282710.9% of flowCommon StockSEC:0000905718-21-000834:0
Canonical exit: 21 Sept 2021 (T+90)
25 of 30 declarations
关于 Reneo Pharmaceuticals, Inc.
Reneo Pharmaceuticals, Inc. 是一家总部位于美国的生物制药公司，已在纳斯达克市场上市。历史上，该公司致力于开发针对罕见遗传性线粒体疾病的疗法，目标是满足高度未满足的医疗需求领域。Reneo 于 2014 年开始运营，其早期战略围绕着主要资产 REN001 展开，该资产正在多个罕见代谢疾病适应症中推进。公司总部位于加利福尼亚州欧文，其运营足迹主要与临床开发、监管工作和公司职能相关，而非商业制造或广泛的销售基础设施。([sec.gov](https://www.sec.gov/Archives/edgar/data/1637715/000095017023014812/rphm_2022_annual_report.pdf?utm_source=openai)) 从行业角度来看，Reneo 是一家临床阶段的生物技术公司，这意味着其价值主张取决于研究执行、知识产权和临床里程碑，而非经常性产品收入。因此，其竞争地位更多地由利基孤儿病市场中的科学差异化而非规模决定。公司的开发重点包括原发性线粒体肌病、长链脂肪酸氧化障碍和糖原贮积病 V 型（McArdle 病），所有这些疾病都代表着相对较小的患者群体，但如果能获得临床数据和监管批准，则具有重要的商业机会。([nasdaq.com](https://www.nasdaq.com/press-release/vtv-therapeutics-announces-2021-first-quarter-financial-results-and-provides?utm_source=openai)) 近期的一项重大进展是 2024 年宣布的战略转型：Reneo 与 OnKure（一家专注于精准医疗的临床阶段肿瘤公司）达成并随后获得了股东批准的全股票合并协议。两家公司宣布，合并后的实体将在纳斯达克以股票代码 OKUR 交易，并更名为 OnKure Therapeutics, Inc.。此次合并被视为整合资源并将上市公司平台转向肿瘤学的一种方式，而 Reneo 自身的传统线粒体项目则被淡化。Reneo 2024 年第二季度业绩也提到了暂停 mavodelpar 开发活动和相关的成本削减，这突显了其正在从原有战略转型。([nasdaq.com](https://www.nasdaq.com/press-release/reneo-pharmaceuticals-announces-stockholder-approval-merger-onkure-2024-10-02?utm_source=openai)) 对于法语投资者而言，Reneo 应被视为一家在纳斯达克上市的市值非常小的美国生物技术公司，其历史根植于罕见病药物开发，近期已转型为肿瘤学公司。核心投资案例一直由管线选择权、临床执行风险和资产负债表考量驱动，而非既定的经营利润。实际上，该公司的概况是一个转型中的生物技术平台：科学专业化、高风险，并且高度依赖战略交易和未来的临床数据。
